Previous 10 | Next 10 |
Myriad Genetics (NASDAQ: MYGN ) fiscal Q1 results : More news on: Myriad Genetics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
It's been feast or famine for Myriad Genetics (NASDAQ: MYGN) this year. The stock has skyrocketed more than 50% in a single day . And it has dropped by nearly that much in one day as well. The genetic testing company announced its fiscal 2020 first-quarter results after the market close...
Image source: The Motley Fool. Myriad Genetics Inc (NASDAQ: MYGN) Q1 2020 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading
The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Myriad Genetics, Inc. (MYGN) Q1 2020 Earnings Conference Call November 4, 2019 4:30 PM ET Company Participants Scott Gleason – Vice President-Investor Relations Mark Capone – President and Chief Executive Officer Bryan Riggsbee – Chief Financial Officer Co...
Myriad Genetics (NASDAQ: MYGN ): Q1 Non-GAAP EPS of $0.08 misses by $0.23 ; GAAP EPS of -$0.28 misses by $0.29 . More news on: Myriad Genetics, Inc., Earnings news and commentary, Consumer stocks news, Read more ...
Total First-Quarter Revenues of $186.3 Million Excluding Out-of-Period Adjustments Revenue Would Have Been $197.5 Million First-Quarter Diluted EPS of ($0.28) and Adjusted EPS of $0.08 SALT LAKE CITY, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, ȁ...
Myriad Genetics (NASDAQ: MYGN ) is scheduled to announce Q1 earnings results on Monday, November 4th, after market close. The consensus EPS Estimate is $0.31 (-27.9% Y/Y) and the consensus Revenue Estimate is $202.34M (flat Y/Y). Over the last 2 years, MYGN has beaten EPS estimates 7...
AAN , ACOR , ADUS , AOSL , APLE , APTS , AWR , BHF , BKD , BKH , BWXT , CBT , CC , CDE , CDEV , CHGG , CPE , DIOD , DK , DOOR , ED , ETH , EVBG , EVER , FICO , FN , FRPT , FRTA , FTSI , GRPN , HHC , HIG , HLIO , HPR , HR , HTZ , IFF , ITRI , JKHY , KA...
SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra ® will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being hel...
News, Short Squeeze, Breakout and More Instantly...
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy 1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, a...
2024-05-12 19:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...